Novo Surges Most in a Month as Ozempic Outperforms Trulicity in Real-World US Patient Survey
Novo Nordisk’s shares surged the most in a month following positive results from a real-world survey indicating that Ozempic, its flagship diabetes medication, outperformed Eli Lilly’s Trulicity among certain U.S.…